Results 1–20 of 72 for vpas

Did you mean pas?

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access (20 Oct 2023)

Will Quince: ...investment in our impact assessment of recent updates to the statutory scheme for branded medicines pricing, which operates alongside the voluntary scheme for branded medicines pricing and access (VPAS). The Government’s 2023 impact assessment of updates to the statutory scheme is available at the following link: https://www.gov.uk/government/consultations/proposed-update-...

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access (17 Oct 2023)

Will Quince: The metrics report for the 2019 voluntary scheme for branded medicines pricing and access (VPAS) will be published according to standard timelines. VPAS metrics are published twice yearly following the VPAS Operational Review meeting with the Association of the British Pharmaceutical Industry. The latest metrics were published on 11 August 2023 and are currently available through an internal...

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access (17 Oct 2023)

Will Quince: The Department has no plans to re-instate the reports to Parliament on the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which were a requirement under the 2014 The Pharmaceutical Price Regulation Scheme (PPRS). This requirement was removed from the 2019 VPAS with the agreement of the Association of the British Pharmaceutical Industry. We are open to ideas about how a...

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access (11 Sep 2023)

Will Quince: The voluntary scheme for branded medicines pricing and access (VPAS) includes strong commercial incentives to launch new products in the form of freedom of list pricing and exemptions from payments for innovative medicines containing a new active substance. At the mid-scheme review for the 2019 VPAS, the Department and NHS England concluded that the scheme had been effective in supporting...

Written Answers — Department for Science, Innovation and Technology: Voluntary Scheme for Branded Medicines Pricing and Access: Life Sciences (11 Sep 2023)

George Freeman: ...kinds of investment in our Impact Assessment of updates to the Statutory Scheme for branded medicines pricing, which operates alongside voluntary scheme for branded medicines pricing and access (VPAS). The Government’s 2023 Impact Assessment of updates to the Statutory Scheme can be found here: www.gov.uk/government/consultations/review-of-the-scheme-to-...

Written Answers — Department of Health and Social Care: Life Sciences: Foreign Investment in UK (25 Jul 2023)

Lord Markham: The Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) payment percentages have been at or below those projected when the scheme was agreed. Recent increases to payment percentages reflect the scheme working as intended to adjust for increased sales of branded medicines to the National Health Service, which is the result of the positive access and uptake environment within the...

Written Answers — Department for Science, Innovation and Technology: Life Sciences: Foreign Investment in UK (25 Jul 2023)

Viscount Camrose: No direct assessment has been made. However, payment rates in the 2019 VPAS have been below those forecast when the scheme was agreed with industry. The Government remains firmly committed to negotiating a mutually beneficial scheme that supports better patient outcomes, a strong UK life sciences industry, and the sustainability of NHS spend on branded medicines.

Written Answers — Department of Health and Social Care: Drugs: Licensing (13 Jul 2023)

Will Quince: ...accepted, and plans to further review the implementation of its methods towards the end of 2023. New innovative medicines do not pay the voluntary scheme for branded medicines pricing and access (VPAS) rebate rate for the first three years after marketing authorisation. The National Health Service is a unique proposition for global life sciences companies. With a single commercial deal, a...

Written Answers — Department of Health and Social Care: Life Sciences (13 Jul 2023)

Will Quince: ...drugs and medicines to National Health Service patients faster, including through the delivery of the Life Sciences Vision. The current voluntary scheme for branded medicines pricing and access (VPAS) finishes at the end of this year. Negotiations on a successor scheme began in May and aim to conclude later this year to take effect from January 2024. We are open to ideas about how a...

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access ( 3 Jul 2023)

Will Quince: The voluntary scheme for branded medicines pricing and access (VPAS) includes strong commercial incentives in the form of freedom of list pricing and exemptions from payments for medicines containing a new active substance. Smaller companies are specifically supported through payment exemptions for those with under £5 million sales and a taper for companies between £5 million and £25...

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access (29 Jun 2023)

Will Quince: The voluntary scheme for branded medicines pricing and access (VPAS) includes strong commercial incentives to launch new products in the form of freedom of list pricing and exemptions from payments for medicines containing a new active substance. In addition, the scheme made commitments to improve the access environment for medicines which has been done through the publication of NHS...

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access (27 Jun 2023)

Lord Markham: ...investment in our impact assessment of recent updates to the statutory scheme for branded medicines pricing, which operates alongside the voluntary scheme for branded medicines pricing and access (VPAS). There are several factors which influence company investment decisions in any particular country or region. Available evidence suggests that supply side factors, such as availability of...

Written Answers — Department for Science, Innovation and Technology: Life Sciences (26 Jun 2023)

Viscount Camrose: ...sector to ensure we deliver the Life Sciences Vision. Supporting the life sciences industry and future innovation is an objective of the voluntary scheme for branded medicines pricing and access (VPAS), and DSIT is working with DHSC to understand how VPAS has impacted investment and innovation in the UK. The Government has considered in broad terms the link between volume-based rebate...

Cancer Medicines: Appraisals — [Carolyn Harris in the Chair] (13 Jun 2023)

Will Quince: My hon. Friend is absolutely right, and I regularly meet the pharmaceutical industry, not least because of VPAS, which I will come on to discuss because it has been raised by a number of Members. While I understand the concern, it is absolutely right that assessment of clinical and cost effectiveness reflect up-to-date clinical pathways, evidence and evaluative methods and processes. However,...

Branded Health Service Medicines (Costs) (Amendment) Regulations 2023 - Motion to Regret (25 May 2023)

Lord Markham: ...but we would agree, I think, that it is quite sensible that the two are aligned. If you had large disparities between the two, you would disadvantage, for instance, the members who have joined the VPAS system.

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access ( 4 May 2023)

Anne Marie Morris: ...and Social Care, whether medicines funded under the Innovative Medicines Fund will be included in the calculation of that company's rebate under the Voluntary Pricing Scheme for Branded Medicines (VPAS).

Branded Medicines Voluntary Scheme and the Life Sciences Vision ( 3 May 2023)

Anne Marie Morris: ...about medicine prices as against the life sciences vision. Indeed, in my proposals, all the things the Minister set out as issues for industry are things that should and could be part of the VPAS debate. The reason is that it is the only debate where Government and industry agree between them what they are going to do—there is no other opportunity. I urge the Minister to make the most of...

Written Answers — Department of Health and Social Care: NHS: Drugs ( 3 May 2023)

Will Quince: ...we get value for money for spending on medicines. The UK has two mechanisms for controlling overall spend on branded medicines: the voluntary scheme for branded medicines pricing and access (VPAS) and the statutory scheme for branded medicine pricing. Both schemes apply UK-wide. The VPAS caps sales of branded medicines to the National Health Service, with the cap growing by 2% each year....

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access ( 3 May 2023)

Anne Marie Morris: ...State for Health and Social Care, whether medicines funded through the cancer drugs fund are included in the calculation of the rebate due under the voluntary pricing scheme for branded medicines (VPAS).

Written Answers — Department of Health and Social Care: Voluntary Scheme for Branded Medicines Pricing and Access (25 Apr 2023)

Will Quince: We have been working directly with industry to understand the impact of changes to VPAS on investments into the UK life sciences sector. We remain firmly committed to VPAS and to working with the pharmaceutical industry to create an environment that facilitates innovation for the development of medicines in the UK.


1 2 3 4 > >>

Create an alert

Advanced search

Find this exact word or phrase

You can also do this from the main search box by putting exact words in quotes: like "cycling" or "hutton report"

By default, we show words related to your search term, like “cycle” and “cycles” in a search for cycling. Putting the word in quotes, like "cycling", will stop this.

Excluding these words

You can also do this from the main search box by putting a minus sign before words you don’t want: like hunting -fox

We also support a bunch of boolean search modifiers, like AND and NEAR, for precise searching.

Date range

to

You can give a start date, an end date, or both to restrict results to a particular date range. A missing end date implies the current date, and a missing start date implies the oldest date we have in the system. Dates can be entered in any format you wish, e.g. 3rd March 2007 or 17/10/1989

Person

Enter a name here to restrict results to contributions only by that person.

Section

Restrict results to a particular parliament or assembly that we cover (e.g. the Scottish Parliament), or a particular type of data within an institution, such as Commons Written Answers.

Column

If you know the actual Hansard column number of the information you are interested in (perhaps you’re looking up a paper reference), you can restrict results to that; you can also use column:123 in the main search box.